90 related articles for article (PubMed ID: 17474969)
1. Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'?
Ziemssen F; Folprecht G; Ziemssen T
Acta Ophthalmol Scand; 2007 Aug; 85(5):573-4; author reply 574-5. PubMed ID: 17474969
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.
Kernt M; Neubauer AS; Kampik A
Acta Ophthalmol Scand; 2007 Feb; 85(1):119-20. PubMed ID: 17244226
[No Abstract] [Full Text] [Related]
3. Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
Utman SA; Dhillon B
Retina; 2008 Apr; 28(4):667; author reply 667-8. PubMed ID: 18398378
[No Abstract] [Full Text] [Related]
4. Bevacizumab for corneal neovascularization.
Jacobs DS; Lim M; Carrasquillo KG; Rosenthal P
Ophthalmology; 2009 Mar; 116(3):592-3; author reply 593-4. PubMed ID: 19264217
[No Abstract] [Full Text] [Related]
5. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
Lee K; Yang H; Lim H; Lew HM
Retina; 2009; 29(10):1409-17. PubMed ID: 19816242
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab: the need for controlled studies to move forward.
Buys YM
Can J Ophthalmol; 2007 Dec; 42(6):789. PubMed ID: 18059506
[No Abstract] [Full Text] [Related]
7. The effects of intravitreal ophthalmic medications on intraocular pressure.
Wu H; Chen TC
Semin Ophthalmol; 2009; 24(2):100-5. PubMed ID: 19373694
[TBL] [Abstract][Full Text] [Related]
8. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
Shin JP; Lee JW; Sohn BJ; Kim HK; Kim SY
J Glaucoma; 2009; 18(8):589-94. PubMed ID: 19826387
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions.
Jonas JB; Libondi T; Schlichtenbrede F; Schmidbauer M
Acta Ophthalmol; 2010 Mar; 88(2):e24-5. PubMed ID: 19493250
[No Abstract] [Full Text] [Related]
10. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.
Fakhraie G; Katz LJ; Prasad A; Eslami Y; Sabour S; Zarei R; Moghimi S
J Glaucoma; 2010 Mar; 19(3):212-8. PubMed ID: 19593201
[TBL] [Abstract][Full Text] [Related]
11. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Kumar V; Ghosh B; Raina UK; Goel N
Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
[No Abstract] [Full Text] [Related]
13. The effect of topical bevacizumab on corneal neovascularization.
Kim SW; Ha BJ; Kim EK; Tchah H; Kim TI
Ophthalmology; 2008 Jun; 115(6):e33-8. PubMed ID: 18439681
[TBL] [Abstract][Full Text] [Related]
14. Consecutive appearance of corneal subepithelial infiltrates after intravitreous bevacizumab injections.
Bourla DH; Dotan A; Weinberger D; Bourla N; Kremer I
Cornea; 2010 Jun; 29(6):686-7. PubMed ID: 20458242
[TBL] [Abstract][Full Text] [Related]
15. Monitoring systemic complications of intraocular medications.
Pulido JS
Can J Ophthalmol; 2010 Jun; 45(3):215-7. PubMed ID: 20628419
[No Abstract] [Full Text] [Related]
16. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion--a matched-pairs analysis.
Guthoff R; Meigen T; Hennemann K; Schrader W
Ophthalmologica; 2010; 224(2):126-32. PubMed ID: 19738392
[TBL] [Abstract][Full Text] [Related]
17. Intravitreous bevacizumab injection: an experimental study in New Zealand white rabbits.
Cortez RT; Ramirez G; Collet L; Thakuria P; Giuliari GP
Arch Ophthalmol; 2010 Jul; 128(7):884-7. PubMed ID: 20625050
[TBL] [Abstract][Full Text] [Related]
18. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
19. Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern.
Avery RL
J AAPOS; 2009 Aug; 13(4):329-31. PubMed ID: 19683181
[No Abstract] [Full Text] [Related]
20. Reflux after intravitreal injection of bevacizumab.
Boon CJ; Crama N; Klevering BJ; van Kuijk FJ; Hoyng CB
Ophthalmology; 2008 Jul; 115(7):1270; author reply 1271. PubMed ID: 18598829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
